LAB SEC Filings - STANDARD BIOTOOLS INC 10-K, 10-Q, 8-K Forms
This page on Stock Titan provides comprehensive access to Standard BioTools Inc.'s (NASDAQ: LAB) SEC filings, including 10-K, 10-Q, 8-K, and insider trading forms. It details recent material events such as the SomaScan business divestiture to Illumina, equity incentive plan updates, and executive compensation awards. The platform offers AI-powered summaries to help investors quickly digest key information from these regulatory disclosures.
Standard BioTools Inc (LAB) Stock Price Quote Today & Current Price Chart
This article provides the current stock price quote and chart for Standard BioTools Inc (LAB), emphasizing that Capital.com is a smart investment app for online trading.
Standard BioTools Inc (LAB) Stock Price Quote Today & Current Price Chart
This article provides a real-time stock price quote and current price chart for Standard BioTools Inc (LAB). It also references online trading via Capital.com.
Short Interest in Standard BioTools Inc. (NASDAQ:LAB) Declines By 18.5%
Short interest in Standard BioTools Inc. (NASDAQ:LAB) decreased by 18.5% in March, totaling 8,281,198 shares as of March 13th. Institutional investors now own about 53.74% of the stock, with several large investors increasing their stakes. The company recently beat revenue and EPS estimates but remains unprofitable, with analysts holding a consensus "Reduce" rating and a target price of $1.35.
Standard BioTools (NASDAQ:LAB) Stock Rating Upgraded by Wall Street Zen
Standard BioTools (NASDAQ:LAB) has been upgraded by Wall Street Zen from a "sell" to a "hold" rating, although the consensus among analysts remains "Reduce" with a target price of $1.35. The company recently exceeded earnings estimates, reporting $0.05 EPS against an expected ($0.03) and $23.8M in revenue versus $18.5M, but it continues to be unprofitable with a negative net margin. Institutional investors hold a significant portion of the stock, with some increasing their positions.
Standard BioTools Inc. $LAB Shares Purchased by Mak Capital One LLC
Mak Capital One LLC significantly increased its stake in Standard BioTools (NASDAQ:LAB) by 184.6% in the third quarter of 2025, now holding 15,931,806 shares valued at approximately $20.7 million. Despite beating earnings and revenue estimates for the last quarter, Standard BioTools remains unprofitable and carries a consensus "Reduce" rating from analysts with an average price target of $1.35. The stock currently trades near $0.96.
Long Focus Capital Management LLC Acquires 1,292,804 Shares of Standard BioTools Inc. $LAB
Long Focus Capital Management LLC increased its stake in Standard BioTools Inc. (NASDAQ:LAB) by 12.8% in the third quarter, acquiring an additional 1,292,804 shares. The firm now holds 11,362,804 shares, representing approximately 2.95% of the company, valued at $14.77 million. Despite beating quarterly earnings estimates with $0.05 EPS and $23.8 million in revenue, Standard BioTools remains unprofitable with a negative return on equity and net margin, leading analysts to a "Reduce" rating with a target price of $1.35.
Standard BioTools 2025 10-K: Revenue $85.3M, EPS $(0.20)
Standard BioTools reported 2025 revenue of $85.3 million, a 6% decline year-over-year, and an improved net loss per share of $(0.20). The company's strategic actions included consolidating R&D, relocating its headquarters, reducing its workforce, and divesting the SomaScan business to focus on mass cytometry and microfluidics. Despite a revenue decrease, operating losses narrowed due to reduced expenses.
Standard BioTools Inc. $LAB Stake Boosted by Casdin Capital LLC
Casdin Capital LLC increased its stake in Standard BioTools Inc. (NASDAQ:LAB) by 1.9% in the third quarter of 2026, making LAB its fourth-largest holding. Despite this significant institutional investment, Wall Street analysts have a "Reduce" consensus rating for Standard BioTools, with a target price of $1.35. The company reported better-than-expected EPS and revenue last quarter but remains unprofitable, with institutional investors owning 53.74% of the stock.
Standard BioTools (NASDAQ:LAB) Cut to "Sell" at Wall Street Zen
Wall Street Zen has downgraded Standard BioTools (NASDAQ:LAB) from a "hold" to a "sell" rating. The company, despite beating recent earnings and revenue estimates, remains unprofitable with a negative net margin. Analysts anticipate a negative EPS for the current year, and institutional investors have recently adjusted their holdings in LAB.
AI Investing Insights - Official Homepage - Intellectia AI™
This page provides news and event updates for LAB (Standard BioTools) stock, including its Q4 2025 earnings report, full-year 2025 revenue projections, and the completed sale of SomaLogic to Illumina. Standard BioTools reported strong Q4 revenue, exceeding expectations, and provided revenue guidance for fiscal year 2026. The company also highlighted its strengthened financial position and strategic flexibility following the SomaLogic sale.
Director at Standard BioTools (LAB) takes RSUs instead of cash pay
Troy Cox, a director at Standard BioTools (LAB), reported receiving 57,264 restricted stock units (RSUs) valued at $1.17 per share, instead of $67,000 in cash compensation for his board services. These RSUs increase his direct stake to 376,586 shares and will vest in four equal installments throughout 2026, conditional on his continued board service. This move aligns his compensation more closely with shareholder interests through equity incentives.
STANDARD BIOTOOLS (LAB) director takes 51,282 RSUs in lieu of $60K cash
Thomas D. Carey, a director at STANDARD BIOTOOLS INC. (LAB), has reported the acquisition of 51,282 Restricted Stock Units (RSUs) valued at $1.17 per share. These RSUs were accepted in place of $60,000 in cash compensation for his board service and will vest in four equal quarterly installments throughout 2026, contingent on his continued service. Following this transaction, Carey directly holds a total of 245,340 shares of common stock in the company.
Eli Casdin boosts equity stake in STANDARD BIOTOOLS (LAB) with 52,991 RSUs
Eli Casdin, a director and 10% owner of STANDARD BIOTOOLS (LAB), has increased his equity stake by receiving 52,991 restricted stock units (RSUs) valued at $1.17 per share. These RSUs were accepted in lieu of $62,000 in cash compensation for his board service and will vest in four equal installments throughout 2026, contingent on his continued board membership. Following this transaction, Casdin directly holds over 2.95 million common shares, with additional indirect holdings through various investment funds he is associated with.
LAB Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of STANDARD BIOTOOLS INC (LAB), detailing its income statement, balance sheet, cash flow, and key financial ratios through fiscal year 2024, derived from SEC filings. It highlights the company's rapid revenue growth (64% YoY) but also significant unprofitability, negative operating and free cash flow, and low earnings quality. The analysis includes financial health scores, Piotroski F-Score, and interest coverage, indicating moderate overall financial health with concerns regarding profitability and cash generation.
Standard BioTools (NASDAQ:LAB) Upgraded to Hold at Wall Street Zen
Wall Street Zen has upgraded Standard BioTools (NASDAQ:LAB) from a "sell" to a "hold" rating, contributing to the stock's consensus "Reduce" rating with an average $1.35 price target. The company recently surpassed quarterly earnings and revenue expectations ($0.05 EPS vs. $-0.03 consensus; $23.8M revenue vs. $18.5M), despite remaining unprofitable with a negative return on equity and net margin. Insider activity shows significant buying, with Casdin Partners purchasing 150,000 shares and total insider acquisitions reaching 350,000 shares in the last three months, bringing insider ownership to 23.16%.
Standard BioTools (LAB) SVP disposes shares for tax withholding
Sean Mackay, SVP & Chief Business Officer of Standard BioTools Inc. (LAB), reported a tax-related share disposition on February 23, 2026. A total of 19,661 shares of common stock were withheld to cover tax obligations from previously vested restricted stock units, at a price of $1.15 per share. After this transaction, Mackay directly holds 760,174 shares of Standard BioTools common stock.
Standard BioTools Inc. (LAB) Stock Analysis: Unveiling a 32% Upside Potential Amidst Challenging Metrics
Standard BioTools Inc. (LAB) shows a potential 32.48% upside despite significant financial challenges, including declining revenue, negative EPS, and cash flow issues. The company, formerly Fluidigm Corporation, is innovating in proteomics and genomics, supported by academic partnerships. Analysts maintain a cautious but positive outlook, with a target price suggesting potential growth for risk-tolerant, long-term investors.
Standard BioTools (LAB) Q4 Profit Challenges Longstanding Unprofitable Narrative
Standard BioTools (LAB) reported a mixed set of FY 2025 numbers, with a Q4 profit of US$0.04 EPS, a notable improvement against its full-year loss. While bears point to the company's 5.3x P/S multiple despite ongoing losses and forecasted unprofitability, bulls see the Q4 profit as a potential early sign of improved margins due to cost synergies. The company's DCF fair value of US$4.37 contrasts sharply with its current US$1.17 share price, creating tension between valuation models and the company's current operating trends.
Standard BioTools Inc reports results for the quarter ended December 31 - Earnings Summary
Standard BioTools Inc. has released its earnings summary for the quarter that ended on December 31. The report, issued via Reuters, provides financial results for the specified period.
Standard BioTools Q4 2025 Results: Profit on $23.8M Revenue - News and Statistics
Standard BioTools Inc. reported a Q4 2025 net income of $19.3 million on $23.8 million in revenue, translating to $0.05 per share, or an adjusted $0.06 per share. Despite the profitable quarter, the company recorded a net loss of $74.9 million for the full fiscal year 2025, with annual revenue reaching $85.3 million. Looking ahead, Standard BioTools forecasts its current full-year revenue to be between $80 million and $85 million.
Preview: Standard BioTools's Earnings
Standard BioTools (NASDAQ: LAB) is set to release its quarterly earnings report, with analysts widely expecting an EPS of $-0.04. Investors are keenly watching to see if the company surpasses estimates and provides positive guidance, especially after missing EPS by $0.05 last quarter, which led to a 4.2% stock price drop. The company's shares are currently trading at $1.13 and have seen an 11.9% decline over the past 52 weeks, indicating potential dissatisfaction among long-term shareholders.
Standard BioTools (LAB) trims 2025 loss, boosts margins and cash after SomaLogic deal
Standard BioTools (LAB) reported a reduced net loss for 2025 and improved gross margins despite a slight dip in revenue, thanks to significant cost savings and efficiency gains. Following the SomaLogic deal, the company boasts a strong cash position of approximately $550 million, which it plans to leverage for disciplined M&A, and has issued a 2026 revenue guidance of $80–$85 million. The financial results indicate a strategic focus on operational streamlining and a strong balance sheet to drive long-term value.
Standard BioTools (NASDAQ:LAB) Announces Earnings Results
Standard BioTools (NASDAQ:LAB) announced earnings results, reporting an EPS of $0.05 against a consensus estimate of ($0.03) and revenue of $23.8 million, exceeding analysts' expectations. Despite outperforming estimates, the company remains unprofitable with a negative net margin of 86.06%. Following the report, shares traded up approximately 3.6%, though Wall Street analysts maintain a cautious "Reduce" rating with a consensus price target of $1.35.
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Standard BioTools announced strong financial results for Q4 and full year 2025, with revenue from Continuing Operations reaching $23.8 million and $85.3 million respectively. The company fully operationalized over $40 million in cost savings and ended the year with approximately $550 million in cash and investments after the SomaLogic transaction, positioning it for inorganic growth and profitability in 2026. CEO Michael Egholm highlighted disciplined execution, significant cost reductions, and a strong balance sheet to drive long-term shareholder value.
Standard Biotools earnings beat by $0.10, revenue topped estimates
Standard Biotools (NASDAQ: LAB) reported strong financial results for the fourth quarter, surpassing analyst expectations with an EPS of $0.050, which was $0.10 higher than the estimated $-0.050. The company also exceeded revenue forecasts, posting $23.8M against a consensus estimate of $18.57M. For fiscal year 2026, Standard Biotools projects revenue between $80.000M and $85.000M, aligning with analyst estimates.
LAB Forecasts Revenue Between $80 Million and $85 Million for FY
Standard BioTools Inc (LAB) has projected its fiscal year 2026 revenue to be between $80 million and $85 million. The company, which specializes in medical devices and instruments, operates with a strong balance sheet due to low debt-to-equity and strong liquidity, despite facing profitability challenges and being in a distress zone according to the Altman Z-Score. Valuation metrics show a complex scenario, with the stock approaching oversold territory and institutional ownership at 73.85%, complemented by recent insider buying.
Standard BioTools Reports Fourth Quarter and Full Year 2025 Financial Results
Standard BioTools Inc. announced its financial results for Q4 and full year 2025, reporting revenue of $23.8 million and $85.3 million respectively from continuing operations. The company successfully implemented over $40 million in annualized cost savings and ended the year with approximately $550 million in cash and investments after selling SomaLogic to Illumina, aiming for positive adjusted EBITDA and cash flow by the end of 2026. Standard BioTools plans to leverage its strong financial position and NOL carryforwards for disciplined M&A and long-term shareholder value.
Tax withholding trims Standard BioTools (LAB) CFO share stake
Standard BioTools (LAB) CFO Hanjoon Alex Kim reported a tax-related share disposition. The company withheld 12,740 shares of common stock at $1.15 per share to cover tax obligations upon the vesting of restricted stock units. Following this, Kim directly owns 2,407,346 common shares, which includes 5,000 shares acquired via an employee stock purchase plan.
Preview: Standard BioTools's Earnings
Standard BioTools (NASDAQ: LAB) is set to release its quarterly earnings report on Tuesday, February 24, 2026, with analysts expecting an EPS of $-0.04. The company's past performance shows that its stock price dropped after missing EPS estimates in the previous quarter. Long-term shareholders may be concerned as shares are down 11.9% over the last 52 weeks, trading at $1.13 as of February 20.
LAB - STANDARD BIOTOOLS INC Latest Stock News & Market Updates
This page provides the latest news and market updates for Standard BioTools Inc. (LAB), an analytical laboratory instrument manufacturer. It covers financial results, strategic transactions, partnerships, and product launches, offering insights for investors and researchers on the company's evolution, cost management, and participation in the life sciences ecosystem. The article also lists key stock data and recent announcements including financial results and product launches from 2022.
Standard BioTools Inc expected to post a loss of 7 cents a share - Earnings Preview
Standard BioTools Inc (LAB) is projected to report a loss of 7 cents per share in its upcoming earnings announcement. This information is based on an earnings preview from Refinitiv. The article provides a brief outlook on the company's expected financial performance.
Standard BioTools (LAB) Expected to Announce Quarterly Earnings on Tuesday
Standard BioTools (LAB) is set to release its Q4 2025 earnings after market close on Tuesday, February 24th, 2026. Analysts predict an EPS of ($0.03) and revenue of $18.5 million. The company has seen recent insider buying, with Casdin Partners acquiring 150,000 shares in December and institutional investors also adjusting their stakes, while analysts have a consensus "Reduce" rating with a $1.35 price target.
Standard BioTools Inc. (LAB) Stock Analysis: Unpacking a 39.64% Potential Upside in the Healthcare Sector
Standard BioTools Inc. (LAB), a medical devices company specializing in proteomics and genomics, shows a potential upside of 39.64% despite current financial challenges. Trading at $1.11, the stock is below its moving averages, with a low RSI suggesting it might be oversold. While the company faces revenue decline, negative EPS, and significant free cash flow issues, its innovative technological platforms and cautiously optimistic analyst ratings indicate long-term growth potential for risk-tolerant investors.
Standard BioTools Inc.'s (NASDAQ:LAB) Popularity With Investors Under Threat As Stock Sinks 27%
Standard BioTools Inc. (NASDAQ:LAB) has seen its stock drop 27% in the last month, contributing to an 11% decline over the past year. Despite a strong prior revenue growth of 80% last year and 55% over three years, analysts predict a 21% annual revenue decline for the next three years, contrasting with an expected 7.7% industry growth. This raises concerns about the company's price-to-sales ratio, which is currently similar to the industry median, suggesting investors might be overlooking future revenue declines.
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after the U.S. market closes. The company specializes in providing standardized next-generation technologies, including mass cytometry and microfluidics, to support biomedical research. They work with various laboratories globally, focusing on translational and clinical research.
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after the U.S. market closes. The company specializes in next-generation technologies for biomedical research, focusing on mass cytometry and microfluidics to support the development of medicines. Standard BioTools works with academic, government, pharmaceutical, and biotechnology organizations to advance translational and clinical research.
Standard BioTools to Announce Fourth Quarter and Full Year 2025 Financial Results on February 24, 2026
Standard BioTools Inc. (NASDAQ: LAB) announced that it will release its fourth quarter and full year 2025 financial results on Tuesday, February 24, 2026, after the U.S. market closes. The company, which provides essential next-generation technologies for biomedical research, focuses on delivering reliable insights in health and disease using mass cytometry and microfluidics. Standard BioTools partners with academic, government, pharmaceutical, and biotechnology laboratories worldwide to advance research in areas like oncology and immunology.
Standard BioTools Strengthens Balance Sheet with Major Divestiture
Standard BioTools has completed the divestiture of SomaLogic to Illumina for $350 million, significantly boosting its cash reserves to approximately $550 million with potential for an additional $75 million in earnouts and long-term royalty fees. This strategic move aims to strengthen the company's financial position, enable a focus on core operations, and provide flexibility for strategic acquisitions, following strong operational performance in 2025. Investors are awaiting the detailed Q4 and full-year 2025 financial results for further insights into the company's future outlook.
Standard BioTools completes sale of SomaLogic to Illumina for $350 million
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina, Inc. for $350 million upfront, with potential for an additional $75 million in earnout payments. This acquisition strengthens Illumina's genomics market position and provides Standard BioTools with a 2% royalty on net revenues from SOMAmer-based NGS library preparation kits for 10 years. Standard BioTools emerges from this transaction in a strong financial position, aiming for positive adjusted EBITDA in 2026 and planning strategic acquisitions to drive growth.
Standard BioTools completes sale of SomaLogic to Illumina for $350 million
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina, Inc. for an upfront cash payment of $350 million, with potential earnout payments up to an additional $75 million. This acquisition strengthens Illumina's position in the genomics market and provides Standard BioTools with royalty streams and a co-exclusive license for certain intellectual property. Standard BioTools estimates its post-transaction cash and cash equivalents at approximately $550 million, aiming for strategic acquisitions and positive adjusted EBITDA by 2026.
Standard BioTools Completes $350 Million Sale of SomaLogic to Illuminia
Standard BioTools has completed the $350 million sale of SomaLogic to Illumina. Separately, Unity Software reported impressive fourth-quarter financial results, with revenue increasing 35% year-over-year to $609 million, exceeding analyst estimates. However, Unity also reported a quarterly loss of 66 cents per share.
Standard BioTools completes sale of SomaLogic to Illumina for $350 million
Standard BioTools Inc. has finalized the sale of SomaLogic to Illumina, Inc. for $350 million upfront, with potential earnout payments up to $75 million. This acquisition bolsters Illumina's presence in the genomics market, while Standard BioTools aims to use its strengthened financial position to pursue strategic acquisitions and achieve positive adjusted EBITDA in 2026. This move is part of Standard BioTools' strategic transformation, making it more focused and financially robust.
Standard BioTools Completes Major Proteomics Business Divestiture
Standard BioTools (LAB) has finalized the sale of its aptamer-based and functional proteomics business, including SomaLogic, to Illumina for up to $425 million plus royalties. This divestiture allows Standard BioTools to focus on its mass cytometry and microfluidics operations, with approximately $550 million in cash. The company aims for inorganic growth and positive adjusted EBITDA in 2026, while analysts currently rate LAB stock as a Hold with a $1.50 price target.
Standard BioTools (LAB) Concludes Sale of SomaLogic for $425 Mil
Standard BioTools (LAB) has completed the sale of SomaLogic to Illumina for a total potential value of $425 million, including an upfront payment and contingent milestones. This strategic move aims to strengthen Standard BioTools' financial position and enable future mergers and acquisitions, despite the company currently facing significant financial challenges like declining revenue and operating margins. The company's financial health indicators, including an Altman Z-Score in the distress zone, highlight the need to address operational inefficiencies to improve investor confidence.
Standard BioTools Inc. Completes $350 Million Sale of SomaLogic to Illumina, Enhancing Financial Position for Growth Strategy
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina for $350 million upfront, with potential total proceeds of up to $425 million. This transaction significantly strengthens Standard BioTools' financial position, providing approximately $550 million in cash and cash equivalents to fund future growth through disciplined mergers and acquisitions. The company aims to achieve positive adjusted EBITDA by 2026, marking a major step in its strategic transformation.
Standard BioTools Completes Sale of SomaLogic to Illumina
Standard BioTools Inc. has completed the sale of SomaLogic to Illumina for $350 million upfront cash, with potential earnouts up to $425 million and royalties. This transaction significantly strengthens Standard BioTools' financial position, providing approximately $550 million in cash and cash equivalents, which will be used to pursue inorganic growth strategies. The company aims for positive adjusted EBITDA in 2026, marking a major milestone in its strategic transformation.
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Standard BioTools (NASDAQ:LAB) has demonstrated encouraging financial trends, with a 34% reduction in cash burn and an 80% increase in operating revenue over the last year. Despite burning US$98 million, the company holds US$195 million in cash, providing a two-year runway. Analysts project the company will reach breakeven before exhausting its cash, alleviating concerns about its cash burn.
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Standard BioTools (NASDAQ:LAB) has a cash runway of about two years, based on its current cash reserves and burn rate. However, analysts predict the company will reach free cash flow break-even before exhausting its cash. The company's cash burn decreased by 34% last year, and its operating revenue grew by an impressive 80%, indicating healthy growth.
Here's Why We're Not At All Concerned With Standard BioTools' (NASDAQ:LAB) Cash Burn Situation
Standard BioTools (NASDAQ:LAB) has a cash runway of about two years based on its US$195m cash and US$98m annual burn, but analysts expect the company to break even before then. The company has reduced its cash burn by 34% and grown operating revenue by 80% over the last year, indicating healthy progress. Despite its cash burn relative to market capitalization being 17%, the company should be able to raise more capital if needed without significant trouble.
